Table 1 Baseline demographic and clinical characteristics
Overall cohort (N = 353) | Randomly extracted cohort (N = 100) | |||
|---|---|---|---|---|
Anagliptin (n = 177) | Sitagliptin (n = 176) | Anagliptin (n = 50) | Sitagliptin (n = 50) | |
Age, year | 68 ± 10 | 68 ± 9 | 67 ± 8 | 68 ± 9 |
Female | 67 (38) | 72 (41) | 19 (38) | 18 (36) |
Body mass index, kg/m2 | 26.5 ± 4.0 | 25.9 ± 3.5 | 26.1 ± 3.5 | 24.7 ± 2.7 |
Systolic blood pressure, mm Hg | 134 ± 16 | 132 ± 16 | 130 ± 14 | 134 ± 19 |
Diastolic blood pressure, mm Hg | 74 ± 12 | 71 ± 11 | 70 ± 11 | 71 ± 10 |
Smoker | 92 (52) | 103 (59) | 26 (52) | 31 (62) |
Current smoker | 30 (17) | 24 (14) | 7 (14) | 8 (16) |
Past smoker | 62 (35) | 79 (45) | 19 (38) | 23 (46) |
Non-drinker | 102 (58) | 102 (58) | 35 (70) | 26 (52) |
Hypertension | 137 (77) | 133 (76) | 38 (76) | 36 (72) |
Coronary artery disease | 80 (45) | 79 (45) | 23 (46) | 19 (38) |
Stroke | 26 (15) | 26 (15) | 7 (14) | 5 (10) |
Treatment | ||||
Renin–angiotensin–aldosterone system inhibitor | 107 (60) | 99 (56) | 29 (58) | 27 (54) |
Strong statina | 142 (80) | 136 (77) | 37 (74) | 39 (78) |
Ezetimibe | 18 (10) | 12 (7) | 6 (12) | 1 (2) |
Metformin | 87 (49) | 84 (48) | 26 (52) | 18 (36) |
Sulfonylurea | 46 (26) | 37 (21) | 13 (26) | 10 (20) |
Thiazolidine | 25 (14) | 31 (18) | 9 (18) | 10 (20) |
Insulin | 13 (7) | 15 (9) | 4 (8) | 7 (14) |
Other glucose-lowering drugs | 27 (15) | 18 (10) | 9 (18) | 5 (10) |